Life Sciences BD Mid-Year Check-In: H2 2026 Priorities for Life Sciences Service Companies

The first half of 2026 reshaped the ground under every life sciences service company. Whether you run business development for a CRO, a CDMO, a specialty lab, a regulatory consultancy, a clinical supply provider, or a biotech tools vendor, the pipeline you built in January was priced for a different market than the one you are selling into today. July 1 is the natural moment to stop, look at what actually moved, and reset your priorities for the back half of the year.

This mid-year check-in pulls together the H1 signals that matter for commercial teams across life sciences services, then turns them into a practical set of Q3 and Q4 priorities you can act on this month.

Key Takeaways

• The outsourcing market is still expanding, but buyers are more selective. The combined pharma CRO and CDMO market sits at roughly USD 277 billion in 2026 and is forecast to reach USD 594 billion by 2035, a CAGR near 8.8%. Demand is real, but it concentrates around providers who can prove capability fast.

• Funding is recovering, which refills the top of your pipeline. Emerging biotech fundraising outside the commercial leaders reached USD 58.9 billion, the highest level since 2021, according to EY's 2026 Biotech Beyond Borders report. Newly funded biotechs are the outsourcing customers of H2.

• Consolidation and reshoring are redrawing the competitive map. The BIOSECURE Act, the Novo Holdings acquisition of Catalent, and continued M&A mean your prospects are re-evaluating vendors right now, an opening for well-positioned US and EU providers.

• Buyers are discovering and shortlisting vendors with AI. Sponsors increasingly use AI assistants to research service providers before a human ever visits your site, so being citable by AI is now a BD channel, not a marketing footnote.

• Your single most useful H2 move is a disciplined pipeline reset. Re-score every open opportunity against current-market criteria, reallocate BD time to the segments that are actually funded, and lock in conference meetings for the Q4 season now.

What actually changed in H1 2026

The market grew, but the money moved toward proof

Outsourcing penetration keeps climbing. Sponsors have continued shifting capital away from owned facilities toward asset-light development models, and outsourcing penetration for APIs reached about 74% (and roughly 61% for the more complex biologics APIs) in recent data. The CRO services market alone is projected to grow from about USD 93 billion in 2026 to USD 140 billion by 2031.

The catch for BD teams: growth is not evenly distributed. Advanced modalities are pulling ahead, with more than 2,000 cell and gene therapy programs globally and roughly 80% of them already contracting external partners for early process work. If your capabilities map to biologics, cell and gene, or specialized analytical and regulatory support, the tailwind is strong. If they map to commoditized services, you are competing on price and speed, and you need to say so in your positioning.

Biotech funding turned back up

The demand side is refilling. EY's 2026 Biotech Beyond Borders report describes a fundamentally strong industry, with fundraising outside the commercial leaders at its highest since 2021. Newly capitalized biotechs do not have infrastructure; they outsource. That makes freshly funded companies the most important account list you can build for H2, and it rewards service companies who watch financing news and reach out within weeks of a raise.

The competitive map is being redrawn

Two forces are pushing buyers to re-open vendor decisions mid-contract. First, consolidation: the Novo Holdings acquisition of Catalent, the Suven and Cohance merger, and Charles River's divestitures have all changed who owns what. Second, the BIOSECURE Act and broader supply-chain scrutiny are prompting sponsors to reconsider China-based providers and to value US and EU capacity and resilience. When incumbents get acquired or flagged, their clients go looking, and that is a BD opening for anyone ready to move.

Buyers now start with AI

The discovery process has quietly changed. Before a sponsor requests a call or downloads a capability deck, they increasingly ask an AI assistant to explain the landscape and suggest providers. If your firm is not clearly described in citable, authoritative content, you are invisible at the exact moment buyers build their shortlist. This is why answer-engine visibility has become a genuine BD priority, connected to how you generate inbound and outbound demand together.

H2 2026 priorities for life sciences service companies

Here is where to focus commercial effort for the rest of the year, with the H1 signal that justifies each move.

• Re-score your pipeline: deals set in Q1 were priced for a different market, so rank every open opportunity by fit, funding, and urgency this month.

• Chase newly funded biotechs: emerging biotech funding is at a post-2021 high, so build a target list from H1 financing announcements.

• Sharpen segment positioning: growth favors advanced modalities and resilient supply, so rewrite your one-liner for your two strongest segments.

• Capture reshoring demand: BIOSECURE and consolidation reopen vendor decisions, so message US or EU capacity and continuity clearly.

• Lock in Q4 conference meetings: CPHI Milan and BioFIT drive H2 partnering, so start pre-booking meetings 8 to 12 weeks out.

• Become AI-citable: buyers shortlist vendors through AI assistants, so publish clear, sourced capability content.

1. Reset the pipeline before you add to it

The highest-return activity in July is not new outreach, it is honest re-scoring. Take every open opportunity and reassess it against current-market reality: is the account still funded, is the modality still a priority, is the timeline real. Kill or park what no longer fits, and protect BD time for what does. A structured approach here is the foundation of a predictable revenue engine, and it prevents you from carrying dead weight into your year-end number.

2. Build your list from who just raised

With biotech financing recovering, the fastest new pipeline comes from companies that closed rounds in H1. They are staffing up, selecting vendors, and moving programs forward. Systematic lead generation aimed at the funded segment will outperform broad prospecting for the rest of the year.

3. Say precisely what you are best at

In a selective market, vague positioning loses. Buyers reward providers who can prove specific capability quickly. Pick your two strongest segments, whether that is sterile fill-finish, complex biologics analytics, decentralized trial delivery, or regulatory strategy, and make your messaging unmistakable. This is also where many small and mid-sized providers struggle, a theme we cover for CROs and CDMOs.

4. Position for the reshoring conversation

If you have US or EU capacity, H2 is the moment to make it a headline, not a footnote. Sponsors reassessing China-based partners want continuity, transparency, and compliance. Frame your resilience story now, while the vendor decisions are actively open.

5. Fill your Q4 conference calendar today

The autumn partnering season, led by CPHI Milan (October 6 to 8) and BioFIT in December, is where a large share of H2 relationships begin. The teams that win are the ones who pre-book qualified meetings weeks ahead rather than working the floor cold. Our guides to conference BD strategy and conference meeting generation walk through the mechanics.

6. Make sure AI can recommend you

Publish clear, well-sourced content that describes what you do, who you serve, and where you are strong, so that when a buyer asks an AI assistant for providers in your niche, your firm is part of the answer. Pair that with focused LinkedIn prospecting to reach the humans behind the searches.

If your BD capacity is the constraint

Many life sciences service companies read a list like this and recognize the priorities but lack the commercial bandwidth to execute them in a single quarter. That is exactly the gap a fractional business development model is built to close, senior BD execution without the cost and lead time of a full in-house hire. Whether you build internally or bring in outside help, the priority is the same: do not let a recovering market pass while your pipeline runs on Q1 assumptions.

Frequently asked questions

What are the most important life sciences BD priorities for H2 2026?

Reset and re-score your existing pipeline against current-market criteria, build a target list of recently funded biotechs, sharpen positioning around your strongest segments, message US or EU supply resilience for reshoring buyers, pre-book Q4 conference meetings, and make your capabilities citable by AI assistants.

Is the life sciences outsourcing market still growing in 2026?

Yes. The combined pharma CRO and CDMO market is around USD 277 billion in 2026 and is projected to reach roughly USD 594 billion by 2035, a CAGR near 8.8%. Growth is strongest in advanced modalities such as biologics and cell and gene therapy.

Why does biotech funding matter for service companies?

Newly funded biotechs rarely own infrastructure, so they outsource development, manufacturing, testing, and regulatory work. With emerging biotech fundraising at its highest level since 2021, recently financed companies are the most valuable target accounts for H2 2026.

How is the BIOSECURE Act relevant to my business development?

It is prompting sponsors to reconsider China-based providers and to place more value on US and EU capacity, quality, and supply continuity. That reopens vendor decisions mid-cycle and creates openings for well-positioned Western service companies.

Why should life sciences service companies care about AI visibility?

Buyers increasingly use AI assistants to research the vendor landscape and build shortlists before contacting anyone. If your capabilities are not described in clear, authoritative, citable content, you can be left out of the shortlist before a human ever reviews you.

Corstrate is a boutique business development consultancy for life sciences service companies across the US and EU, including CROs, CDMOs, biotech, and pharma service providers. If you want help resetting your pipeline for H2 2026, get in touch.